pantothenate


Also found in: Thesaurus, Medical, Encyclopedia, Wikipedia.
Related to pantothenate: Calcium pantothenate, Pantothenate kinase

pan·to·then·ate

 (păn′tə-thĕn′āt′, păn-tŏth′ə-nāt′)
n.
A salt or ester of pantothenic acid.

pantothenate

(ˌpæntəˈθɛneɪt)
n
(Biochemistry) a widely occurring derivative of pantothenic acid
References in periodicals archive ?
Vitamin & Mineral Products: Calcium amino acid chelate, magnesium amino acid chelate, magnesium gluconate, magnesium citrate, selenomethionine, calcium citrate granular, manganese gluconate, calcium malate, riboflavin granular, D-calcium pantothenate, thiamin, methylcobalamin, inositol hexaphosphate, pyrodoxine, vitamin D3, vitamin K1, vitamin E succinate, D-biotin
The lysine (40, 160, 320 mg/L), or troglitazone (10 [micro]m) containing RPMI media along with 1% antibiotics, 17 [micro]M pantothenate, 1 mM carpylic acid, 200 [micro]M ascorbic acid, 33 [micro]m biotin, 10 mM acetic acid, 10 ng/mL insulin, 0.
They were able to gain information about amino acid metabolism, TCA cycle, gluconeogenesis, glutathione metabolism, pantothenate and CoA biosynthesis, and butanoate metabolism.
Percentage % Chlorpyrifos 13 26 Dichlorvos 12 24 Quinalphos 7 14 Methyl Parathion 4 8 Monocrotophos 3 6 Parathion 3 6 Phorate 3 6 Dimethoate 2 4 Diazinon 1 2 Pantothenate 1 2 Profenofos 1 2 Table 3.
Pantothenate kinase--associated neurodegeneration, unlike other neuroacanthocytosis syndromes, begins in childhood.
05), which prominently includes amino acid metabolism, TCA cycle, gluconeogenesis, glutathione metabolism, pantothenate and CoA biosynthesis, and butanoate metabolism.
15 (Vitamin E acetate) Phase C Ion-Moist Molecular Film (Lipotec SAU) (Water (and) glycerin (and) calcium pantothenate (and) xanthan gum (and) urea (and) caprylyl glycol (and) glycose 5.
Pantothenate kinase-associated neurodegeneration (PKAN), account for up to 50% of cases, and are most commonly caused by autosomal recessive mutations in the PANK2 gene.
Biopharmaceutical company Retrophin (Nasdaq:RTRX) said on Thursday that it has entered into an agreement with the US Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process for a Phase 3 clinical trial evaluating RE-024 for the treatment of pantothenate kinase-associated neurodegeneration (PKAN), a rare, genetic, and life-threatening neurological disorder characterised by a host of progressively debilitating symptoms that typically begin in early childhood.
Diseases related to iron overload in the brain Disease Disease gene Clinical features Pantothenate kinase-associated PANK2 Childhood-onset dystonia neurodegeneration (PKAN) and spasticity Fatty acid FA2H Trouble speaking, gait hydroxylase-associated abnormalities, dystonia and neurodegeneration (FAHN) parkinsonism Neuroferritinopathy FTL Abnormal gait late in disease Too much iron These three genetic diseases belong to a small group of disorders marked by excess iron in the brain.